| __timestamp | AbbVie Inc. | Bristol-Myers Squibb Company |
|---|---|---|
| Wednesday, January 1, 2014 | 4426000000 | 3932000000 |
| Thursday, January 1, 2015 | 4500000000 | 3909000000 |
| Friday, January 1, 2016 | 5833000000 | 4946000000 |
| Sunday, January 1, 2017 | 7040000000 | 6066000000 |
| Monday, January 1, 2018 | 7718000000 | 6547000000 |
| Tuesday, January 1, 2019 | 7439000000 | 8078000000 |
| Wednesday, January 1, 2020 | 15387000000 | 11773000000 |
| Friday, January 1, 2021 | 17446000000 | 9940000000 |
| Saturday, January 1, 2022 | 17414000000 | 10137000000 |
| Sunday, January 1, 2023 | 20415000000 | 10693000000 |
| Monday, January 1, 2024 | 16904000000 | 11949000000 |
Unleashing the power of data
In the competitive landscape of pharmaceuticals, cost efficiency is paramount. This analysis delves into the cost of revenue trends for AbbVie Inc. and Bristol-Myers Squibb Company from 2014 to 2023. Over this period, AbbVie has shown a remarkable increase in cost efficiency, with its cost of revenue growing by approximately 360%, from $4.4 billion in 2014 to $20.4 billion in 2023. In contrast, Bristol-Myers Squibb's cost of revenue increased by about 172%, from $3.9 billion to $10.7 billion in the same timeframe.
AbbVie's strategic investments and operational efficiencies have allowed it to outpace Bristol-Myers Squibb, particularly evident in the 2020-2023 period, where AbbVie's cost of revenue surged by 33%. This data underscores the importance of strategic financial management in maintaining competitive advantage in the pharmaceutical industry.
Eli Lilly and Company vs Bristol-Myers Squibb Company: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: AbbVie Inc. vs Catalent, Inc.
Analyzing Cost of Revenue: AbbVie Inc. and ADMA Biologics, Inc.
Cost of Revenue: Key Insights for AbbVie Inc. and Geron Corporation
Cost Insights: Breaking Down AbbVie Inc. and Evotec SE's Expenses
Cost of Revenue Trends: AbbVie Inc. vs Xencor, Inc.
Cost Insights: Breaking Down AstraZeneca PLC and Bristol-Myers Squibb Company's Expenses
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs CRISPR Therapeutics AG
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Bausch Health Companies Inc.
Cost of Revenue: Key Insights for Bristol-Myers Squibb Company and Agios Pharmaceuticals, Inc.
Bristol-Myers Squibb Company vs Wave Life Sciences Ltd.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bristol-Myers Squibb Company vs Viridian Therapeutics, Inc.